摘要
目的研讨H型高血压患者接受依那普利叶酸治疗的临床效果与其安全性。方法选择在我院诊疗的62例H型高血压患者作随机非盲分组(31例/组)实验,Ⅰ组接受常规基础治疗,Ⅱ组使用依那普利叶酸片治疗,观察评估两组的治疗情况。结果施治前,两组在SBP、DBP及血浆Hcy水平上相比,无统计学意义(P> 0.05);施治后12、24周,Ⅱ组相对Ⅰ组在SBP、DBP及血浆Hcy水平上均显著改善,比较有统计学意义(P<0.05)。两组在实验期间均未出现明显的药物相关性副反应,但在新发脑卒中方面,Ⅱ组相对Ⅰ组的发生率明显降低,比较有统计学意义(P<0.05)。结论对H型高血压患者使用依那普利叶酸片治疗是一种可行、安全的给药方案,值得推荐。
Objective To study the clinical efficacy and safety of H-type hypertensive patients receiving enalapril folate treatment. Methods 62 patients with type H hypertension in our hospital were randomLy divided into 31 groups. Ⅰ group received routine basic treatment, and group Ⅱ used Treatment with enalapril folic acid tablets observed and evaluated the treatment of the two groups. Results Before treatment, there was no significant difference in SBP, DBP and plasma Hcy levels between the two groups（P〉0.05）; at 12 and 24 weeks after treatment, SBP, DBP, and plasma Hcy in group Ⅱ relative to group Ⅰ. The levels were significantly improved, with statistical significance（P〈0.05）. There was no obvious drug-related side reaction in the two groups during the experiment, but in the new stroke of the incidence, group Ⅱ was significantly lower than that in group Ⅰ（P〈0.05）. Conclusion The use of enalapril folic acid tablets for treatment of H-type hypertensive patients is a feasible and safe drug delivery protocol and is worth recommending.
作者
关丽娜
GUAN Li-na(Internal Medicine-Cardiovascular Department,Hulun buir People＇s Hospital,Hulun buir,Inner Mongolia 021008)
出处
《智慧健康》
2018年第25期56-57,共2页
Smart Healthcare
关键词
H型高血压
依那普利叶酸
临床效果
安全性
H-type hypertension
Enalapril folic acid
Clinical efficacy
Safety
